Обзоры (стр. 4 )

14.        , , Миома матки: (патогенез, этиология, диагностика, лечение). Москва: Видар. 2010;244. [Ischenko A. I., Botvin M. A, Lanchinskii V. I. Uterine fibroids: (pathogenesis, etiology, diagnosis, treatment). Moscow: Vidar. 2010;244.

15.        , , Эффективность и безопасность применения аГнРГ «Бусерелин-лонг ФС» у пациенток с эндометриозом в позднем репродуктивном возрасте (клиническое исследование. Российский вестник акушера-гинеколога. 2016;16(5):87—94. [Buianova S. N., Babunashvili E. L., Zubova E. S., Rizhinashvili I. D.  The effectiveness and safety of using aGnRh «Buserelin-long FS» in patients with endometriosis in the later reproductive years (clinical study. Rossiiskii vestnik akushera-ginekologa. 2016;16:5:87—94. (In Russ.)]. https://doi. org 10.17116/rosakush201616587-94

16.        Vercellini P, Crosignani PG, Mangioni C, Imparato E, Ferrari A, De Giorgi O. Treatment with a gonadotrophin releasing hormone agonist before hysterectomy for leiomyomas: Results of a multicentre, randomised controlled trial. Br J Obstet Gynaecol. 1998;105:11:1148—1154. http://dx. doi. org/10.1111/j.1471-0528.1998.tb09967.x

17.        , , Золадекс в комплексном лечении больных с миомой матки (многоцентровое исследование). Российский вестник акушера-гинеколога. 1998;3:52—57. [Krasnopol'skiш V. I., Buнanova S. N., Petrova V. D. Zoladex in complex treatment of patients with uterine myoma (multicenter study). Rossiiskii vestnik akushera-ginekologa. 1998;3:52—57. (In Russ.)].

18.        Britten JL, Minnie Malik M, Levy G, Mendoza M, Catherino WH. Gonadotropin-releasing hormone (GnRH) agonist leuprolide acetate and GnRH antagonist cetrorelix acetate directly inhibit leiomyoma extracellular matrix production. Fertil Steril. 2012;98:5:1299—1307. http://dx. doi. org/10.1016/j. fertnstert.2012.07.1123

19.        Panidis D, Vavilis D, Rousso D, Stergiopoulos K, Kalogeropoulos A. Danazol influences gonadotropin secretion acting at the hypothalamic level. Int J Gynecol Obstet. 1994;45:3:241—246. https://doi. org 10.1016 / 0020-7292 (94) 90249-6

20.        Ke LQ, Yang K, Li CM, Li J. Danazol for uterine fibroids. Cochrane Database Syst Rev 2009; 3. http://dx. doi. org/10.1002/14651858.CD007692.pub2

21.        , Миома матки: проблемы и перспективы начала века. Медицинский совет. 2014;9:30—33. [Radzinskii V. E., Arkhipova M. P. Uterine fibroids: problems and prospects of the beginning of the century. Meditsinskii sovet. 2014;9:30—33. (In Russ.)].

22.        Ishikawa H, Reierstad S, Demura M, Rademaker AW, Kasai T, Inoue M, Usui H, Shozu M, Bulun SE. High aromatase expression in uterine leiomyoma tissues of African-American women. J Clin Endocrinol Metab. 2009;94:1752—1756.  http://dx. doi. org/10.1210/jc.2008-2327

23.        Sumitani H, Shozu M, Segawa T, Murakami K, Yang H, Shimada K, Inoue M.  In situ estrogen synthesized by aromatase P450 in uterine leiomyoma cells promotes cell growth probably via an autocrine/intracrine mechanism. Endocrinology. 2000;141:10:3852—3861. https://doi. org/10.1210/endo.141.10.7719

24.        Song Н, Hao DL, Navaratnam K, Shi G. Aromatase inhibitors for uterine fibroids. Cochrane Database Syst Rev. 2013;10. ttp://dx. doi. org/10.1002/14651858.CD009505.pub2

25.        Mirkin S, Pickar JH. Selective estrogen receptor modulators (SERMs): A review of clinical data. Maturitas. 2015;80:1:52—57. http://dx. doi. org/10.1016/j. maturitas.2014.10.010

26.        Deng L, Wu T, Chen XY, Xie L, Yang J. Selective estrogen receptor modulators (SERMs) for uterine leiomyomas. Cochrane Database Syst. Rev. 2012;10. http://dx. doi. org/10.1002/14651858.CD005287.pub4

27.        Vilos GA, Allaire C, Laberge P-G, Leyland N, Vilos AG, Murji A, Chen I. The Management of Uterine Leiomyomas. J Obstet Gynaecol Canada. 2015;37:2:57—178. http://dx. doi. org/10.1016/S1701-2163(15)30338-8

28.         Расширение возможностей органосохраняющего лечения миомы матки с использованием улипристала ацетата. Гинекология. 2016;18:1:56—60. [Tikhomirov A. L. The empowerment of organ preservation treatment of uterine fibroids using ulipristal acetate. Ginekologiya. 2016;18:1:56—60. (In Russ.)].

29.        Chegini N, Ma C, Tang XM, Williams RS. Effects of GnRH analogues, «add-back» steroid therapy, antiestrogen and antiprogestins on leiomyoma and myometrial smooth muscle cell growth and transforming growth factor-в expression. Mol Hum Reprod. 2002;8:12:1071—1078.  https://doi. org/10.1093/molehr/8.12.1071

30.        Kawaguchi K, Fujii S, Konishi I, Nanbu Y, Nonogaki H, Mori T. Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstet Gynecol. 1989;160:3:637—641. http://dx. doi. org/10.1016/S0002-9378(89)80046-8

31.        Kawaguchi K, Fujii S, Konishi I, Iwai T, Nanbu Y, Nonogaki H, Ishikawa Y, Mori T. Immunohistochemical analysis of oestrogen receptors, progesterone receptors and Ki-67 in leiomyoma and myometrium during the menstrual cycle and pregnancy. Virchows Arch A Pathol Anat Histopathol. 1991;419:4:309—315. http://dx. doi. org/10.1007/BF01606522

32.        Friedman AJ, Daly M, Juneau-Norcross M, Gleason R, Rein MS, Leboff M. Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin «add-back» for 2 years. Hum Reprod. 1994;9:9:1618—1625. http://dx. doi. org/10.1093/oxfordjournals. humrep. a138762

33.        Murji A, Whitaker L, Chow TL, Sobel ML. Selective progesterone receptor modulators (SPRMs) for uterine fibroids. Cochrane Database Syst. Rev. 2017;4. http://dx. doi. org/10.1002/14651858.CD010770.pub2

34.        de Leo V, Morgante G, La Marca A, Musacchio MC, Sorace M, Cavicchioli C, Petraglia F. A benefit-risk assessment of medical treatment for uterine leiomyomas. Drug Saf. 2002;25:11:759—779. PMID: 12222988

35.        Eisinger SH, Meldrum S, Fiscella K, Le Roux HD, Guzick DS. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol. 2003;101:2:243—250. https://doi. org/10.1016/S0029-7844(02)02511-5

36.        Sheni Q, Hua Y, Jiang W, Wenwen Z, Chen M, Zhu X. Effects of mifepristone on uterine leiomyoma in premenopausal women: A meta-analysis. Fertil Steril. 2013;6: http://dx. doi. org/10.1016/j. fertnstert.2013.08.039

37.        Donnez J, Tatarchuk TF, Bouchard P, Puscasiu L, Zakharenko NF, Ivanova T, Ugocsai G, Mara M, Manju JP, Bestel E, Terrill P, Osterloh I, Loumaye E. Ulipristal Acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012a;366:5:409—420. http://dx. doi. org/10.1056/NEJMoa1103182

38.        Donnez J, Tomaszewski J, Vбzquez F, Bouchard P, Lemieszczuk B, Barу F, Nouri K,  Selvaggi L, Sodowski K, Bestel E, Terrill P, Osterloh I, Loumaye E. Ulipristal Acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012b;366:5:421—432. http://dx. doi. org/10.1056/NEJMoa1103180

39.        Donnez J, Vбzquez F, Tomaszewski J, Nouri K, Bouchard P, Fauser BCJM, Barlow DH, Palacios S, Donnez O, Bestel E. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril. 2014;101:6. http://dx. doi. org/10.1016/j. fertnstert.2014.02.008

40.        Donnez J, Hudecek R, Donnez O, Matule D, Arhendt HD, Kasilovskiene Z, Dumitrascu MC, Fernandez H, Barlow DH, Bouchard P, Bart CJMF, Bestel E, Terrill P, Osterloh I, Loumaye E. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertil Steril. 2015;103:2:519—527. http://dx. doi. org/10.1016/j. fertnstert.2014.10.038

41.        , , Стволовые клетки: Учебно-методическое пособие. Минск: БГМУ. 2014. [Mezen N. I., Kvacheva Z. B., Sychik L. M. Stem cells. Minsk. BGMU. 2014. (In Russ.)]. ISBN 978-985-528-982-2.

42.        , , Мезенхимальные стволовые клетки из различных тканей человека: биологические свойства, оценка качества и безопасности для клинического применения. Клеточная трансплантология и тканевая инженерия. 2012;7:1:23—33. (Издательство: Институт стволовых клеток человека, Москва). [Shakhpazyan N. K., Astrelina T. A., Yakovleva M. V. Mesenchymal stem cells from different human tissues: biological properties, evaluation of quality and safety for clinical use. Cell transplantology and tissue engineering. Human Stem Cells Institute Publishing House. 2012;7:1:23—33. (In Russ.)]. ISSN: 2313-1829

43.        Carneiro M. Stem cells and uterine leiomyomas: What is the evidence? JBRA Assist Reprod. 2016;20:1:33—37. http://dx. doi. org/10.5935/1518-0557.20160008

44.        Szotek PP, Chang HL, Zhang L, Preffer F, Dombkowski D, Donahoe PK, Teixeira J. Adult mouse myometrial label-retaining cells divide in response to gonadotropin stimulation. Stem Cells. 2007;25:5:1317—1325. http://dx. doi. org/10.1634/stemcells.2006-0204

45.        OnoM, Maruyama T, Masuda H, Takashi T, Nagashima T, Arase T, Ito M, Ohta K, Uchida H, Asada H, Yoshimura Y, Okano H, Matsuzaki Y. Side population in human uterine myometrium displays phenotypic and functional characteristics of myometrial stem cells. Proc Natl Acad Sci U. S.A. 2007;104:47:18700—18705. http://dx. doi. org/10.1073/pnas.0704472104

46.        Chang HL, Senaratne TN, Zhang L, Szotek PP, Stewart E, Dombkowski D, Preffer F, Donahoe PK, Teixeira J. Uterine leiomyomas exhibit fewer stem/progenitor cell characteristics when compared with corresponding normal myometrium. Reprod Sci. 2010;17:158—167. doi: 10.1177/1933719109348924

47.        Zhou S, Yi T, Shen K, Zhang B, Huang F, Zhao X. Hypoxia: The driving force of uterine myometrial stem cells differentiation into leiomyoma cells. Med Hypotheses. 2011;77:6:985—986. http://dx. doi. org/10.1016/j. mehy.2011.08.026

48.        Mas A, Nair S, Laknaur A, Simуn C, Diamond MP, Al-Hendy A. Stro-1/CD44 as putative human myometrial and fibroid stem cell markers. Fertil Steril. 2015;104:1:225—234.e3. http://dx. doi. org/10.1016/j. fertnstert.2015.04.021

49.        Yin P, Ono M, Moravek MB, Coon JSV, Navarro A, Monsivais D, Dyson MT, Druschitz SA, Malpani SS, Serna VA, Qiang W, Chakravarti D, Julie Kim J, Bulun SE. Human uterine leiomyoma stem/progenitor cells expressing CD34 and CD49b initiate tumors in vivo. J Clin Endocrinol Metab. 2015;100:4:E601–E606. http://dx. doi. org/10.1210/jc.2014-2134

50.        Ding L, Li X, Sun H, Su J, Lin N, Pйault B, Song T, Yang J, Dai J, Hu Y. Transplantation of bone marrow mesenchymal stem cells on collagen scaffolds for the functional regeneration of injured rat uterus. Biomaterials. 2014;35:18:4888—4900. http://dx. doi. org/10.1016/j. biomaterials.2014.02.046

51.        Song T, Zhao X, Sun H, Li X, Lin N, Ding L, Dai J, Hu Y. Regeneration of uterine horns in rats using collagen scaffolds loaded with human embryonic stem cell-derived endometrium-like cells. Tissue Eng Part A. 2015;21:(1–2):353—361. http://dx. doi. org/10.1089/ten. tea.2014.0052

52.        Li X, Ding L, Wang L, Cao Y, Zhu H, Lu J, Li X, Song T, Hu Y, Dai J. Umbilical cord-derived mesenchymal stem cells on scaffolds facilitate collagen degradation via upregulation of MMP-9 in rat uterine scars. Stem Cell Res Ther. 2017;8:1. doi: 10.1186 / s13287-017-0535-0

53.        Li X, Sun H, Lin N, Hou X, Wang J, Zhou B, Xu P, Xiao Z, Chen B, Dai J, Hu Y. Regeneration of uterine horns in rats by collagen scaffolds loaded with collagen-binding human basic fibroblast growth factor. Biomaterials. 2011;32:32:8172—8181. http://dx. doi. org/10.1016/j. biomaterials.2011.07.050

54.        Miyazaki K, Maruyama T. Partial regeneration and reconstruction of the rat uterus through recellularization of a decellularized uterine matrix. Biomaterials. 2014;35:31:8791—8800. http://dx. doi. org/10.1016/j. biomaterials.2014.06.052

55.        Santoso EG, Yoshida K, Hirota Y, Aizawa M, Yoshino O, Kishida A, Osuga Y, Saito S, Ushida T, Furukawa KS. Application of detergents or high hydrostatic pressure as decellularization processes in uterine tissues and their subsequent effects on in vivo uterine regeneration in murine models. PLoS One. 2014;9:7. http://dx. doi. org/10.1371/journal. pone.0103201

56.        Hellstrцm M, Moreno-Moya JM, Bandstein S, Bom E, Akouri RR, Miyazaki K, Maruyama T, Brдnnstrцm M. Bioengineered uterine tissue supports pregnancy in a rat model. Fertil Steril. 2016;106:2:487—496. http://dx. doi. org/10.1016/j. fertnstert.2016.03.048

57.        Elloumi-Hannachi I, Yamato M, Okano T. Cell sheet engineering: A unique nanotechnology for scaffold-free tissue reconstruction with clinical applications in regenerative medicine. Journal of Internal Medicine. 2010;54—70. http://dx. doi. org/10.1111/j.1365-2796.2009.02185.x

58.        Takagi S, Shimizu T, Kuramoto G, Ishitani K, Matsui H, Yamato M, Okano T. Reconstruction of functional endometrium-like tissue in vitro and in vivo using cell sheet engineering. Biochem Biophys Res Commun. 2014;446:1:335—340. http://dx. doi. org/10.1016/j. bbrc.2014.02.107

Поступила 19.03.18